Wednesday, August 17, 2011

Research Identifies How Vitamin D Combats MS


Main Category: Multiple Sclerosis
Also Included In: Nutrition / Diet
Article Date: 17 Aug 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
3 stars3 stars
While for years scientists have noted an association between levels of vitamin D in a person's body and the person's ability to resist or minimize the effects of multiple sclerosis (MS), the mechanism involved has not been established. However new research by Sylvia Christakos, Ph.D., of UMDNJ-New Jersey Medical School (principal investigator) Sneha Joshi (first author, a UMDNJ Ph.D. student), and colleagues (including co-investigator Lawrence Steinman, MD, of Stanford University) appears to have uncovered that process. The study, published in the journal Molecular and Cellular Biology, finds that vitamin D directly terminates the production of a disease-causing protein.

During MS ("EAE" in mice), a damaging protein called interleukin-17 (IL-17) is produced by immune cells in the brain. The investigators, a collaborative team of scientists from the University of Medicine and Dentistry of New Jersey and Stanford University, find that after vitamin D binds to its receptor, the receptor parks itself on the gene that encodes IL-17. By doing so, the receptor occupies a site normally reserved for a protein called NFAT, which is required to turn the gene on. The gene stays off and IL-17 levels plummet.

At the same time, the vitamin D receptor turns on another gene, whose product generates suppressive T cells that combat the destructive action of their IL-17-producing counterparts.

According to the researchers, the mechanism they identify suggests what might be a new path toward pharmaceutical treatment of MS, as well as therapies for other autoimmune diseases that might include rheumatoid arthritis, type 1 diabetes, eczema and psoriasis.

Source: University of Medicine and Dentistry of New Jersey (UMDNJ)

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.


0 Comments:

Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More